Avenue Therapeutics Inc.

1.05+0.0005+0.05%Vol 89.30K1Y Perf -89.14%
Mar 24th, 2023 10:54 DELAYED
BID1.05 ASK1.06
Open1.05 Previous Close1.05
Pre-Market1.06 After-Market-
 0.01 0.95%  - -
Target Price
9.00 
Analyst Rating
— 0.00
Potential %
756.74 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/-100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/-100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
0.43 
Earnings Rating
Neutral
Market Cap5.81M 
Earnings Date
24th Mar 2023
Alpha-0.03 Standard Deviation0.24
Beta1.00 

Today's Price Range

1.031.09

52W Range

0.983016.65

5 Year PE Ratio Range

-9.50-3.30

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-5.41%
1 Month
-6.25%
3 Months
-13.93%
6 Months
-76.67%
1 Year
-89.14%
3 Years
-99.00%
5 Years
-98.72%
10 Years
-

TickerPriceChg.Chg.%
ATXI1.050.00050.05
AAPL158.89-0.0400-0.03
GOOG105.63-0.6300-0.59
MSFT278.991.33000.48
XOM101.29-2.1188-2.05
WFC35.47-1.1400-3.11
JNJ151.180.05000.03
FB196.640.99000.51
GE91.02-0.5700-0.62
JPM123.76-3.0850-2.43
 
Earnings HistoryEstimateReportedSurprise %
Q03 2022--0.45-
Q02 2022--0.03-
Q03 2020-0.10-0.0640.00
Q02 2020-0.10-0.11-10.00
Q01 2020-0.17-0.0852.94
Q04 2019--0.32-
Q03 2019-0.32-0.1456.25
Q02 2019-0.57-0.4324.56
Earnings Per EndEstimateRevision %Trend
9/2021 QR-0.050.00-
12/2021 QR-0.0420.00Positive
12/2021 FY-0.20-300.00Negative
12/2022 FY-0.1814.29Positive
Next Report Date24th Mar 2023
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume89.30K
Shares Outstanding5.53K
Shares Float11.99M
Trades Count145
Dollar Volume94.76K
Avg. Volume619.37K
Avg. Weekly Volume132.57K
Avg. Monthly Volume818.82K
Avg. Quarterly Volume906.74K

Avenue Therapeutics Inc. (NASDAQ: ATXI) stock closed at 1.05 per share at the end of the most recent trading day (a -0.94% change compared to the prior day closing price) with a volume of 118.46K shares and market capitalization of 5.81M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 4 people. Avenue Therapeutics Inc. CEO is Alexandra MacLean.

The one-year performance of Avenue Therapeutics Inc. stock is -89.14%, while year-to-date (YTD) performance is -9.48%. ATXI stock has a five-year performance of -98.72%. Its 52-week range is between 0.983 and 16.65, which gives ATXI stock a 52-week price range ratio of 0.43%

Avenue Therapeutics Inc. currently has a PE ratio of -0.30, a price-to-book (PB) ratio of 14.29, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -870.59%, a ROC of -847.42% and a ROE of 5 775.10%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Avenue Therapeutics Inc., there were 1 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Avenue Therapeutics Inc.’s next earnings report date is 24th Mar 2023.

The consensus rating of Wall Street analysts for Avenue Therapeutics Inc. is (0), with a target price of $9, which is +756.74% compared to the current price. The earnings rating for Avenue Therapeutics Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Avenue Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Avenue Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 17.56, ATR14 : 0.10, CCI20 : -83.66, Chaikin Money Flow : -0.05, MACD : -0.04, Money Flow Index : 77.18, ROC : -0.94, RSI : 40.32, STOCH (14,3) : 10.34, STOCH RSI : 0.03, UO : 45.11, Williams %R : -89.66), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Avenue Therapeutics Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0 (0.00 %)
Moderate Buy
0
0
0 (0.00 %)
Hold
0
0
1 (100.00 %)
Moderate Sell
0
0
0 (0.00 %)
Strong Sell
0
0
0 (0.00 %)
Summary Rating-
0.00
-
0.00
Hold
3.00

Avenue Therapeutics Inc.

Avenue Therapeutics Inc is a specialty pharmaceutical company that develops and markets pharmaceutical products for the acute care setting. It focuses on developing its product candidate, an intravenous (IV) formulation of tramadol HCI (IV Tramadol), for post-operative acute pain.

CEO: Alexandra MacLean

Telephone: +1 781 652-4500

Address: 1140 Avenue of the Americas, New York 10036, NY, US

Number of employees: 4

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

67%33%

Bearish Bullish

58%42%

Bearish Bullish

63%38%

Bearish Bullish

62%38%


News

Stocktwits